Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk Infants
NCT06710925 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk Infants
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 28, 2024
- Completion date
- December 14, 2025
- Enrollment
- 315 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.